MedTrace Logo

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

NCT07235033 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-07

Study results available
· View outcomes & findings →

Summary

This was Cohort B2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.

Conditions

  • Uncomplicated Plasmodium Falciparum Malaria

Interventions

DRUG

KAE609

oral capsules administered in combination with KLU156

DRUG

SoC (Coartem)

Standard of Care

DRUG

KLU156

oral sachet formulation (KAF156+LUM-SDF) administered in combination with cipargamin (KAE609)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-23
Primary Completion
2025-03-05
Completion
2025-03-19

Countries

  • Côte d’Ivoire
  • Gabon
  • Kenya

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07235033 on ClinicalTrials.gov